USD 5.58
(-2.26%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -1.12 USD | -119.61% |
2022 | -0.51 USD | -54.55% |
2021 | -0.33 USD | 17.5% |
2020 | -0.40 USD | -90.48% |
2019 | -0.21 USD | 0.0% |
2018 | -0.21 USD | 58.0% |
2017 | -0.50 USD | -138.1% |
2016 | -0.21 USD | -10.53% |
2015 | -0.19 USD | 62.0% |
2014 | -0.50 USD | 53.7% |
2013 | -1.08 USD | -28.57% |
2012 | -0.84 USD | -82.61% |
2011 | -0.46 USD | -31.43% |
2010 | -0.35 USD | 95.48% |
2009 | -7.74 USD | 53.46% |
2008 | -16.63 USD | -15.81% |
2007 | -14.36 USD | -108.72% |
2006 | -6.88 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | -0.32 USD | -100.0% |
2024 Q3 | -0.29 USD | 9.38% |
2024 Q1 | -0.16 USD | -60.0% |
2023 FY | - USD | -119.61% |
2023 Q4 | -0.10 USD | 80.0% |
2023 Q2 | -0.17 USD | 50.0% |
2023 Q3 | -0.50 USD | -194.12% |
2023 Q1 | -0.34 USD | -78.95% |
2022 Q4 | -0.19 USD | -26.67% |
2022 Q3 | -0.15 USD | -271.29% |
2022 Q1 | -0.13 USD | 18.75% |
2022 Q2 | -0.04 USD | 68.92% |
2022 FY | - USD | -54.55% |
2021 Q3 | 0.03 USD | 145.32% |
2021 Q1 | -0.14 USD | -116.05% |
2021 Q4 | -0.16 USD | -633.33% |
2021 FY | - USD | 17.5% |
2021 Q2 | -0.07 USD | 52.71% |
2020 Q4 | -0.06 USD | 35.2% |
2020 FY | - USD | -90.48% |
2020 Q2 | -0.11 USD | 15.38% |
2020 Q1 | -0.13 USD | -1103.7% |
2020 Q3 | -0.10 USD | 9.09% |
2019 Q2 | -0.12 USD | -26.58% |
2019 Q3 | 0.01 USD | 108.33% |
2019 FY | - USD | 0.0% |
2019 Q1 | -0.09 USD | -1015.29% |
2019 Q4 | -0.01 USD | -208.0% |
2018 Q1 | -0.10 USD | -585.0% |
2018 Q4 | -0.01 USD | 77.09% |
2018 FY | - USD | 58.0% |
2018 Q3 | -0.04 USD | 47.6% |
2018 Q2 | -0.07 USD | 27.01% |
2017 Q1 | -0.18 USD | -38.46% |
2017 Q3 | -0.21 USD | -61.54% |
2017 Q2 | -0.13 USD | 27.78% |
2017 FY | - USD | -138.1% |
2017 Q4 | 0.02 USD | 109.52% |
2016 Q3 | 0.04 USD | -33.33% |
2016 FY | - USD | -10.53% |
2016 Q4 | -0.13 USD | -425.0% |
2016 Q2 | 0.06 USD | 135.29% |
2016 Q1 | -0.17 USD | -226.92% |
2015 FY | - USD | 62.0% |
2015 Q2 | -0.14 USD | 0.0% |
2015 Q1 | -0.14 USD | -1500.0% |
2015 Q3 | 0.14 USD | 200.0% |
2015 Q4 | -0.05 USD | -137.14% |
2014 Q1 | -0.17 USD | 34.62% |
2014 Q2 | -0.22 USD | -29.41% |
2014 Q3 | -0.12 USD | 45.45% |
2014 Q4 | 0.01 USD | 108.33% |
2014 FY | - USD | 53.7% |
2013 Q1 | -0.25 USD | 39.02% |
2013 Q2 | -0.33 USD | -32.0% |
2013 Q3 | -0.24 USD | 27.27% |
2013 Q4 | -0.26 USD | -8.33% |
2013 FY | - USD | -28.57% |
2012 Q4 | -0.41 USD | -559.16% |
2012 FY | - USD | -82.61% |
2012 Q1 | -0.21 USD | -40.0% |
2012 Q3 | -0.06 USD | 58.53% |
2012 Q2 | -0.15 USD | 28.57% |
2011 Q1 | -0.10 USD | -590.91% |
2011 Q2 | -0.14 USD | -41.7% |
2011 Q3 | -0.08 USD | 45.5% |
2011 Q4 | -0.15 USD | -96.59% |
2011 FY | - USD | -31.43% |
2010 Q3 | -0.08 USD | 46.73% |
2010 Q1 | -0.50 USD | 74.62% |
2010 Q4 | -0.01 USD | 82.1% |
2010 FY | - USD | 95.48% |
2010 Q2 | -0.15 USD | 70.0% |
2009 FY | - USD | 53.46% |
2009 Q1 | -2.35 USD | 3.69% |
2009 Q4 | -1.97 USD | 16.17% |
2009 Q3 | -2.35 USD | -115.6% |
2009 Q2 | -1.09 USD | 53.62% |
2008 Q4 | -2.44 USD | 0.0% |
2008 FY | - USD | -15.81% |
2008 Q1 | -5.12 USD | 0.0% |
2007 Q1 | -1.88 USD | 0.0% |
2007 FY | - USD | -108.72% |
2006 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Xeris Biopharma Holdings, Inc. | -0.45 USD | -148.889% |
Arrowhead Pharmaceuticals, Inc. | -1.91 USD | 41.361% |
Viridian Therapeutics, Inc. | -5.31 USD | 78.908% |
Organovo Holdings, Inc. | -1.60 USD | 30.0% |